Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial (vol 10, pg 583, 2000)

Authors
Murphy, MP Beaman, ME Clark, LS Cayouette, M Benson, L Morris, DM Polli, JW
Citation
Mp. Murphy et al., Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial (vol 10, pg 583, 2000), PHARMACOGEN, 11(2), 2001, pp. 185-185
Citations number
1
Categorie Soggetti
Pharmacology & Toxicology
Journal title
PHARMACOGENETICS
ISSN journal
0960314X → ACNP
Volume
11
Issue
2
Year of publication
2001
Pages
185 - 185
Database
ISI
SICI code
0960-314X(200103)11:2<185:PCGAAE>2.0.ZU;2-R